IDXG

Interpace Biosciences, Inc.

A molecular diagnostics company that helps doctors tell whether a suspicious thyroid nodule is cancerous, so patients can avoid needless surgery. Its lab tests, ThyGeNEXT® and ThyraMIR®, read DNA, RNA and microRNA to gauge the risk of malignancy. The business began in 2014 as the diagnostic arm of PDI, a pharmaceutical sales-services firm, and became its own company in 2015. The name "Interpace" plays on "interface," reflecting its role as a bridge between diagnosis and treatment.